Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing
Abstract Background Higher mortality of COVID-19 patients with lung disease is a formidable challenge for the health care system. Genetic association between COVID-19 and various lung disorders must be understood to comprehend the molecular basis of comorbidity and accelerate drug development. Metho...
Saved in:
Main Author: | Asim Bikas Das (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SARS-CoV-2: Virology and Drug Repurposing Approaches
by: Ratika Rahmasari, et al.
Published: (2020) -
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
by: Jiri Patocka, et al.
Published: (2021) -
Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing
by: Charlotte Kern, et al.
Published: (2021) -
Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity-Opportunity for Repurposed Chemotherapy of COVID-19 Infection
by: Maryam S. Al-Motawa, et al.
Published: (2020) -
The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation
by: Gates, Lyndsey Elaine, et al.
Published: (2020)